Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.

Wey MC, Fernandez E, Martinez PA, Sullivan P, Goldstein DS, Strong R.

PLoS One. 2012;7(2):e31522. doi: 10.1371/journal.pone.0031522. Epub 2012 Feb 22.

2.

Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.

Goldstein DS, Sullivan P, Holmes C, Miller GW, Alter S, Strong R, Mash DC, Kopin IJ, Sharabi Y.

J Neurochem. 2013 Sep;126(5):591-603. doi: 10.1111/jnc.12345. Epub 2013 Jul 22.

3.

Functional significance of aldehyde dehydrogenase ALDH1A1 to the nigrostriatal dopamine system.

Anderson DW, Schray RC, Duester G, Schneider JS.

Brain Res. 2011 Aug 23;1408:81-7. doi: 10.1016/j.brainres.2011.06.051. Epub 2011 Jun 26.

4.

Aldehyde dehydrogenase 2 in sporadic Parkinson's disease.

Michel TM, Käsbauer L, Gsell W, Jecel J, Sheldrick AJ, Cortese M, Nickl-Jockschat T, Grünblatt E, Riederer P.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S68-72. doi: 10.1016/S1353-8020(13)70018-X.

PMID:
24262192
5.

Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.

Goldstein DS, Sullivan P, Cooney A, Jinsmaa Y, Kopin IJ, Sharabi Y.

J Neurochem. 2015 Apr;133(1):14-25. doi: 10.1111/jnc.13042. Epub 2015 Feb 25.

PMID:
25645689
6.

Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease.

Casida JE, Ford B, Jinsmaa Y, Sullivan P, Cooney A, Goldstein DS.

Chem Res Toxicol. 2014 Aug 18;27(8):1359-61. doi: 10.1021/tx5002223. Epub 2014 Jul 24.

7.

3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis.

Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS.

Brain Res. 2003 Nov 7;989(2):205-13.

PMID:
14556942
8.

Identification of aldehyde dehydrogenase 1A1 modulators using virtual screening.

Kotraiah V, Pallares D, Toema D, Kong D, Beausoleil E.

J Enzyme Inhib Med Chem. 2013 Jun;28(3):489-94. doi: 10.3109/14756366.2011.653353. Epub 2012 Mar 1.

PMID:
22380773
9.

Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate.

Jinsmaa Y, Florang VR, Rees JN, Anderson DG, Strack S, Doorn JA.

Chem Res Toxicol. 2009 May;22(5):835-41. doi: 10.1021/tx800405v.

10.
11.

Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal.

Florang VR, Rees JN, Brogden NK, Anderson DG, Hurley TD, Doorn JA.

Neurotoxicology. 2007 Jan;28(1):76-82. Epub 2006 Aug 1.

PMID:
16956664
12.
13.

The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.

Ekstrand MI, Galter D.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S185-8. doi: 10.1016/S1353-8020(09)70811-9. Review.

PMID:
20082987
14.

Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.

Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Björklund A.

J Neurosci. 2002 Apr 1;22(7):2780-91.

15.

Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism.

Chiu CC, Yeh TH, Lai SC, Wu-Chou YH, Chen CH, Mochly-Rosen D, Huang YC, Chen YJ, Chen CL, Chang YM, Wang HL, Lu CS.

Exp Neurol. 2015 Jan;263:244-53. doi: 10.1016/j.expneurol.2014.09.016. Epub 2014 Sep 28.

16.

Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease.

Pickrell AM, Pinto M, Hida A, Moraes CT.

J Neurosci. 2011 Nov 30;31(48):17649-58. doi: 10.1523/JNEUROSCI.4871-11.2011.

17.
18.

Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

Goldberg NR, Fields V, Pflibsen L, Salvatore MF, Meshul CK.

Neurobiol Dis. 2012 Mar;45(3):1051-67. doi: 10.1016/j.nbd.2011.12.024. Epub 2011 Dec 14.

PMID:
22198503
19.

Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects.

Nagatsu T, Sawada M.

J Neural Transm Suppl. 2007;(72):113-20. Review.

PMID:
17982884
20.

Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity.

Vermeer LM, Florang VR, Doorn JA.

Brain Res. 2012 Sep 20;1474:100-9. doi: 10.1016/j.brainres.2012.07.048. Epub 2012 Jul 31.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk